Eli Lilly and Oxford, England-based Sitryx entered an exclusive global licensing and research collaboration. The two companies will work to develop up to four preclinical compounds discovered by Sitryx for autoimmune diseases.
Shares of Amarin Corporation were down more than 70 percent in trading after a judge ruled that generic companies can go ahead and seek approval of generic versions of the drug manufacturer’s heart disease drug Vascepa.
Johnson & Johnson is moving forward with a vaccine candidate for COVID-19, with human testing starting during September and the first batches available under potential emergency use authorization expected in the first part of 2021.
As COVID-19 threatens the global supply chain, join FierceHealthcare and FiercePharma on March 30th through April 1st for a free virtual event on What’s Next.
A summary of daily biopharma industry news regarding the novel coronavirus trending on March 27, 2020, with the FDA now working with 220 test developers.
One of the key takeaways from BIO-Europe Spring 2020, which was held virtually March 23-27, was that there is a keen need for greater collaboration and communications among the biotech community, government, non-governmental organizations and the public.
As COVID-19 continues to expand across the globe, more pharmaceutical companies are hitting the brakes on clinical trials as part of an effort to ease the burden on doctors and facilities needed to treat patients combating the disease.
Sanofi Pasteur, the vaccines business for French pharma giant Sanofi, and Massachusetts-based Translate Bio have partnered to develop a novel messenger RNA (mRNA) vaccine for COVID-19.
Foster City, California-based SutroVax closed on a Series D preferred stock financing worth $110 million, which was co-led by new investors RA Capital Management and Janus Henderson Investors.
Social distancing measures for COVID-19 are having an impact on the planned merger of Mylan and Pfizer’s off-patent business, Upjohn.